Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra study

This article was originally published in The Tan Sheet

Executive Summary

Advance copy released in April by the American Journal of Health-System Pharmacy contains "serious and damaging inaccuracies" about herbal products and should be pulled from publication in the journal's May 15 issue, Washington, D.C.-based law firm Hyman, Phelps & McNamara says in a letter to AJHSP. The legal counsel to AHPA's Ephedra Committee says the study by Arkansas researcher Bill Gurley, PhD, misrepresents the safety of ephedra products, improperly lumps illegal street drugs with supplements, misrepresents the presence of norpseudoephedrine in supplements and incorrectly asserts ephedra products are related to amphetamine. AJHSP said the study underwent standard peer review and was posted on the journal's Web site prior to hard copy publication in the interests of public safety; the journal has no plans to halt print distribution. In general, the study found ephedra alkaloid content differed markedly from supplement label claims (1"The Tan Sheet" April 24, p. 16)

You may also be interested in...

Ephedra Alkaloid Content Markedly Different From Label Claims - Study

Controlled, human trials are needed to determine the safety and efficacy of ephedra supplements containing stimulant ingredients, University of Arkansas for Medical Sciences College of Pharmacy researchers say in a study slated to appear in the May 15 issue of the American Journal of Health-System Pharmacy.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts